Matthew Wongchenko
Genesys (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Prostate Cancer Treatment and Research, Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research
Most-Cited Works
- → Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy(2019)1,004 cited
- → Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial(2016)994 cited
- → Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis(2018)651 cited
- → Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial(2017)466 cited
- → An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells(2016)345 cited
- → Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial(2021)316 cited
- → Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure(2017)269 cited
- → Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients(2019)234 cited
- → Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2(2016)214 cited
- → A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types(2018)210 cited